Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9932446 | 0.85 | LMNA (0.63) | SMN1; SMN2LMNAL3MBTL1MAPTHTT | |
| SCHEMBL5581831 | 0.81 | LMNA (0.70) | SMN1; SMN2LMNAL3MBTL1MAPTHTT | |
| SCHEMBL22268177 | 0.81 | IDO1 (0.56) | SMN1; SMN2LMNAL3MBTL1MAPTIDO1 | |
| SCHEMBL25257764 | 0.81 | HTT (0.53) | SMN1; SMN2LMNAL3MBTL1MAPTHTT | |
| SCHEMBL13654753 | 0.81 | ALDH1A1 (0.46) | LMNAL3MBTL1 | |
| SCHEMBL25575859 | 0.81 | GLA (0.46) | SMN1; SMN2LMNAL3MBTL1MAPT | |
| SCHEMBL29592964 | 0.80 | LMNA (0.68) | SMN1; SMN2LMNAL3MBTL1MAPTHTT | |
| SCHEMBL1455796 | 0.80 | MEN1 (0.46) | SMN1; SMN2LMNAMAPTHSD17B10SYK | |
| SCHEMBL5063193 | 0.80 | LMNA (0.77) | SMN1; SMN2LMNAL3MBTL1MAPTHTT | |
| SCHEMBL23417028 | 0.79 | LMNA (0.55) | SMN1; SMN2LMNAL3MBTL1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20100317624-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-12-16 | — | — | US | disclosed |
| WO-2010142978-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | WO | disclosed |
| US-7718688-B2 | Nitrobenzindoles and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-05-18 | — | — | US | disclosed |
| WO-2010027280-A1 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-03-11 | — | — | WO | disclosed |
| EP-1809603-A4 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2009-09-02 | — | — | EP | disclosed |
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-05-22 | — | — | US | disclosed |
| EP-1809603-A1 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | Auckland Uniservices Limited (NZ) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006043839-A1 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802135-B2 | Lysophosphatidic acid derivative | LPAR4, LPAR2, LPAR1 | SMN1; SMN2 3474/4885LMNA 1148/4885L3MBTL1 1690/4885 |
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | HIF1AN, HYOU1, HIF1A | SMN1; SMN2 4797/4885LMNA 3875/4885L3MBTL1 2243/4885 |
| US-20100317624-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | UROD, UMPS, SLC14A1 | SMN1; SMN2 3639/4885LMNA 2498/4885L3MBTL1 4699/4885 |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | LPAR4, LPAR2, LPAR1 | SMN1; SMN2 3396/4885LMNA 1415/4885L3MBTL1 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.